Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Pacira (PCRX) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.When looking at the last two reports, this specialty drugmaker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 7.77%, on average, in the last two quarters.For the last reported ...

DOMA Perpetual Believes Pacira's Stock Is Undervalued, Presenting an Opportunity to Execute the Largest Buyback in the Company's HistoryMIAMI, April 21, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC (collectively with its affiliates, "DOMA Perpetual" or "We") is a fundamentals-based, value-oriented asset management firm which beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company").Following constructiv ...

Core Viewpoint - Pacira BioSciences, Inc. is committed to enhancing shareholder value through strategic actions aimed at optimizing operational performance and creating sustainable, long-term value for shareholders [1][3] Group 1: Strategic Initiatives - The company has made significant progress in advancing its 5x30 strategy to transition into an innovative biopharmaceutical organization and aims to become a leader in musculoskeletal pain and related areas by 2030 [2] - The Board of Directors has authorized a share repurchase program of up to $300 million, reinforcing confidence in the company's growth strategy and commitment to shareholder value [5] - The company is focused on enhancing operational efficiency and aims to improve gross margins by 5 percentage points over 2024 [5] Group 2: Product Portfolio - Pacira offers three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and iovera®º, which are designed to manage pain without opioids [4] - The company is advancing the development of PCRX-201, a novel locally administered gene therapy aimed at treating prevalent diseases like osteoarthritis [4] Group 3: Future Outlook - Pacira plans to treat more than 3 million patients annually and aims for a double-digit compounded annual growth rate for revenue [5] - The company is expanding its clinical pipeline with five novel programs in development and establishing five new partnerships, including pipeline and commercial agreements [5]

Pacira BioSciences, Inc. (NASDAQ: PCRX ) is basically a specialty pharmaceutical company working on non- opioid pain management therapies. Their commercial products are Exparel, Zilretta, and iovera. It's worth mentioning that the NOPAIN Act creates an interesting secular tailwind for PCRX, as there are My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio ...

-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 -- -- Fresenius also licensed to sell generic bupivacaine liposome injectable suspension in the U.S. without volume limitations beginning in 2039 -- BRISBANE, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform th ...

-- Novel, locally administered gene therapy designed to boost cellular production of anti-inflammatory protein IL-1Ra in the knee -- -- Initial topline results from two-part, randomized, double-blind, active-controlled study expected late 2026 -- BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the first patient has been dosed ...

SASKATOON, Saskatchewan, April 03, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a definitive share purchase agreement with an arm’s length vendor (the “Vendor”) dated April 1, 2025 to acquire a 100% interest in a pre-1954 charter company (the “Charter Company”) in Ontario, Canada (the “Acquisition”). The Corporation has agreed to purchase the Charter Company for $2,090,000, which will be paid using cash on hand ( ...

CONTACT: Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long- acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic ...

Shares of Pacira BioSciences (PCRX) have surged 66.8% in the past six months against the industry’s decline of 8.7%.  The stock has also outperformed the sector and the S&P 500 index during this timeframe.Strong quarterly results, consistent growth in sales of lead drug Exparel and encouraging pipeline progress have boosted investor sentiment.PCRX Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchExparel’s Performance Fuels PCRX GrowthExparel, Pacira’s flagship pain-management pro ...

Group 1 - The article discusses the challenges faced by Pacira BioSciences, Inc. (NASDAQ: PCRX) that have negatively impacted its share price [2] - The investment group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, product sales forecasts, and financial analyses [2] - The author, Edmund Ingham, has extensive experience in biotech consulting and has prepared detailed reports on over 1,000 companies in the sector [2] Group 2 - The article indicates that the author may initiate a long position in PCRX within the next 72 hours, suggesting potential interest in the stock [3] - There is a disclaimer stating that past performance does not guarantee future results, emphasizing the speculative nature of investments in the biotech sector [4]